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Abstract
Background: Endometriosis is associated with chronic subclinical inflammation. C-reactive protein (CRP), a marker
of inflammation, could serve as a biomarker of endometriosis. We tested the hypothesis that a high sensitivity CRP
assay (hsCRP) is more accurate than a classical CRP assay in the detection of subclinical inflammation in plasma of
women with endometriosis.
Methods: CRP levels were measured by hsCRP and classical CRP assays in plasma of 204 women with
endometriosis and 91 women without endometriosis. Both assays were compared with respect to their value for
the diagnosis of endometriosis.
Results: The number of plasma samples with detectable CRP was significantly higher (100%) using the hsCRP assay
when compared to the classical CRP assay (42.7%) (p < 0.0001). Significantly increased CRP plasma levels were found
in women with endometriosis when compared with controls when the hsCRP assay was used in samples obtained
during the luteal phase (p = 0.008). The highest discriminative ability for the diagnosis of endometriosis was also
obtained using the hsCRP assay during the luteal phase, especially for moderate -severe endometriosis. At a cut-off
level of hsCRP > 0.71 mg/L, moderate-severe stages were diagnosed with 80.7% sensitivity and 63.9% specificity
during the luteal phase. Using a similar cut-off value for CRP analyzed by the classical method, moderate-severe
endometriosis was diagnosed with lower sensitivity (67.7%, p = 0.06) and comparable specificity (63.9%).
Conclusions: The hsCRP assay was superior to the classical CRP assay for the detection of low CRP levels and for
revealing subclinical inflammation in plasma of women with endometriosis.
Background
Endometriosis is defined as the presence of endometrial-
like tissue outside the uterine cavity, associated with a
chronic, inflammatory reaction. Although the pathogen-
esis of endometriosis is still controversial, growing evi-
dence indicates a significant role for immunological and
inflammatory factors in the development of endometrio-
sis [1] as demonstrated by increased concentrations of
activated macrophages, cytokines, angiogenic factors,
T cells and B cells [2-4].
Endometriosis can be considered as an inflammatory
disease [5]. C-reactive protein (CRP) is an acute phase
protein and a marker of inflammatory reaction, could
serve as a potential non-invasive biomarker of endome-
triosis. Its production is stimulated by pro-inflammatory
cytokines such as IL-6, IL-1 and TNF-alpha [6] which are
up-regulated in women with endometriosis when com-
pared to controls [1,7].
CRP is widely accepted as a biochemical marker of
systemic inflammation [8] and routinely used as a mar-
ker of infection, inflammation or tissue damage in clini-
cal practice [6]. Moreover, slightly elevated CRP levels
may indicate a low level of chronic inflammatory reac-
tion in patients at risk of developing metabolic syn-
drome, colon cancer and cardiovascular disease [9,10].
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be viewed as a local disease with systemic subclinical man-
ifestation [7]. Data regarding the CRP level in peripheral
blood of endometriosis patients are relatively scarce and
controversial [11-14] probably related to differences in
study design, patient selection and methodology used to
detect CRP levels in peripheral blood. In our study, sam-
ples were collected at a well defined phase of the cycle and
results were corrected for cycle phase, as recommended by
the QUADAS (Quality Assessment of Diagnostic Accuracy
Studies) guidelines [15,16].
Classical automated methods for CRP measurement
typically have limited sensitivity in the low range of CRP
concentrations in peripheral blood [17]. Several hsCRP
assays have been developed with improved sensitivity
and precision at low concentrations of CRP with the
aim to detect subclinical inflammation [17]. Indeed, a
high sensitivity of the assay may be of great importance
to detect low grade inflammation in plasma. Therefore,
we tested the hypothesis that in plasma a high sensitivity
CRP assay (hsCRP assay) is more accurate than a classi-
cal CRP assay (classical CRP) to detect low grade
inflammation in plasma of women with endometriosis.
The development of a reliable and accurate non-inva-
sive diagnosis of endometriosis is one of the hot topics
in endometriosis research. A clinically useful, non-inva-
sive diagnostic test would have a groundbreaking impact
on the patients’ quality of life, on the efficacy of the
available treatments as well as on the financial aspects
of the disease [18].
The diagnostic accuracy of a test is commonly mea-
sured by using a ROC (receiver operating characteristic)
curve analysis. When two different tests are compared,
results are usually described as one test to be more sensi-
tive or specific than the other. However, such results
have only a descriptive character [19] and it is necessary
to analyze statistically the performance (sensitivity and
specificity) of both tests, and this analysis can impact
medical decision making [19]. In this paper we compared
t h ed i a g n o s t i cp e r f o r m a n c eo ft h eh s C R Pa s s a ya n dt h e
classical CRP assay to detect low grade inflammation in
plasma of women with endometriosis.
Methods
This study was approved by the Commission for Medical
Ethics of the Leuven University Hospitals. Plasma
samples were collected for the Endometriosis research
Biobank after obtaining written informed consent from
women undergoing laparoscopic surgery for subfertility
with or without pain at the Leuven University Fertility
Centre (LUFC) since 1999. Plasma samples were col-
lected prior to anaesthesia induction in EDTA tubes, cen-
trifuged at 3000 rpm for 10 minutes at 4°C, aliquoted,
labelled and stored at -80°C till analysis. The time
interval between sample collection and storage in the
-80°C freezer was maximum 1 hour. For each patient,
relevant information (e.g. date of collection, identification
code, clinicopathological data) was entered in the electro-
nic biobank database of the LUFC.
The following exclusion criteria were used: samples
collected from women who were on hormonal medica-
tion at the time of collection, who had been operated
within 6 months prior to the time of collection, or who
had other pelvic inflammatory disease or general diseases
at the time of collection.
A total of 295 plasma samples were selected from 204
women with laparoscopic confirmed endometriosis
(ASRM stage I-II, n = 135; ASRM stage III-IV, n = 69)
and 91 women with laparoscopic excluded endometriosis
at the time of laparoscopic surgery for subfertility with or
without pain at the LUFC during the menstrual (n = 60),
luteal (n = 116) and follicular phase (n = 119) of the cycle
(Table 1).
A power calculation was not done as this was an
exploratory study using plasma samples obtained from
our endometriosis research biobank. Most samples
included in this study have been used in the previously
published study of our group [14] where we evaluated 6
different potential plasma biomarkers (including hsCRP
b u tn o tc l a s s i c a lC R P )w i t ht h ea i mt od e v e l o pad i a g -
nostic panel for a non-invasive test for endometriosis.
In each sample, the level of CRP was measured twice
using 2 different methods: the classical CRP assay (referred
to as CRP), using an automated CRPLX Tina-quant
C-Reactive Protein (Latex) assay (Roche, Vilvoorde,
Belgium) and the high sensitivity CRP assay (referred to as
hsCRP), using a (Latex) HS Tina-quant C-Reactive protein
(latex) high sensitive assay (Roche, Vilvoorde, Belgium).
Both assays are based on the principle of particle-
enhanced immunological agglutination and were per-
formed on a Roche Modular P instrument (Roche,
Vilvoorde, Belgium) at the central laboratories of the
University Hospitals Leuven (Gasthuisberg, Leuven).
Briefly, anti-CRP antibodies coupled to latex microparti-
cles react with CRP in the sample to form an antigen/anti-
body complex leading to agglutination causing turbidity of
the reaction mixture, which is proportional to the CRP
concentration and measured quantitatively.
Table 1 Distribution of study samples according to stage
of endometriosis and menstrual cycle phase
Cycle phase Controls Stage I-II Stage III-IV
Menstrual 19 26 15
Follicular 36 60 23
Luteal 36 49 31
Total per Stage 91 135 69
TOTAL IN STUDY 295
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Page 2 of 9The lower detection limit of the classical CRP assay and
the hsCRP assay was 0.425 mg/L and 0.03 mg/L respec-
tively. The functional sensitivity of the classical CRP assay
and the hsCRP assay was 0.88 mg/L and 0.11 mg/L
respectively.
For hsCRP, the within-run precision was 1.34% CV at
0.55 mg/dl and 0.28% CV at 12.36 mg/dl. Total impreci-
sion was 5.70% CV and 2.51% CV at those concentration
levels.
For CRP, the within-run precision was 2.5% CV at 5.76
mg/L and 0.76% CV at 150.1 mg/L. Total imprecision
was 2.53% CV and 1.8% CV at those concentration levels.
Data are presented as median and range. A p value <
0.05 was considered statistically significant. Samples with
plasma CRP levels below the detection limit of the assay
were included in statistical analysis using the value corre-
sponding with lower detection limit (LLD). Differences in
CRP levels in women with and without endometriosis
were evaluated using the Mann-Whitney test (endometrio-
sis versus controls) and the Kruskal-Wallis test with post
hoc Dunn analysis (minimal-mild endometriosis versus
moderate-severe endometriosis versus controls).
The ROC curve analysis was performed to determine the
diagnostic performance for both the classical CRP assay
and the hsCRP assay separately. The area-under-the-curve
(AUC) is a relative measure of the diagnostic accuracy and
allows comparison of the diagnostic accuracy of different
tests [20]. In our study the AUC was calculated and evalu-
ated based on previously published guidelines and defini-
tions [20,21]. The clinical value of a laboratory test with
AUC values between 0 and 0.5, 0.5-0.7, 0.7-0.9, or > 0.9 can
be defined as zero, limited, moderate, and high, respectively
[20]. The ROC curves were compared by using Analyze-IT
software for Microsoft Excel (Analyse-it Software, Ltd;
Leeds, United Kingdom). The Mc Nemar test for correlated
proportions was used to check differences in sensitivity
between hsCRP and CRP tests as described before [19,22].
The numbers of plasma samples with detectable CRP
levels between both assays were compared by using Chi-
square test. Correlation analysis was performed by calcu-
lating the Spearman coefficient of correlation. The Fisher r
to z transformation test was applied to assess the signifi-
cance of the difference between two Spearman correlation
coefficients. Bland-Altman analysis was performed to
assess the agreement between two methods.
Results
CRP plasma levels: comparison between classical CRP
assay and hsCRP assay in women with endometriosis and
controls (Table 2)
Women with endometriosis versus controls
Overall analysis (all cycle phases combined)
When compared to controls, CRP plasma levels were
comparable (p = 0.12) or not-significantly elevated (p =
0.06) in women with endometriosis using either the
classical CRP assay or the hsCRP assay, respectively
(Table 2).
Separate analysis according to cycle phase (menstrual,
follicular, luteal)
Significantly increased CRP plasma levels were found in
women with endometriosis when compared to controls
when the hsCRP assay was used in samples obtained dur-
ing the luteal phase (p = 0.008), but not in samples
obtained during follicular or menstrual phase (Table 2). No
differences in CRP levels according to cycle phase were
observed when the classical CRP assay was used (Table 2).
Women with minimal-mild endometriosis or moderate-
severe endometriosis versus controls
Overall analysis (all cycle phases combined)
The CRP plasma levels were higher in women with stage
III-IV of endometriosis than in women with stage I-II
endometriosis or than in controls using either the classical
CRP assay (p < 0.0001 or p < 0.0001, respectively) or the
hsCRP assay (p < 0.0001 or p < 0.0001, respectively).
Separate analysis according to cycle phase (menstrual,
follicular, luteal)
When compared to controls, increased CRP plasma
levels were found in women with stage III-IV of endo-
metriosis using either the classical CRP assay or the
hsCRP assay during both the luteal phase (p = 0.0033 or
p = 0.0005, respectively) and the follicular phase (p =
0.038 or p = 0.0025, respectively) but not during the
menstrual phase (Table 2).
Diagnostic performance of hsCRP versus CRP
ROC curve analysis was performed for the classical CRP
assay and the hsCRP assay separately to identify the dis-
criminative power of the tests. Diagnostic performance
was calculated at the optimal cut-off value (based on the
highest sum of sensitivity and specificity). Table 3 illus-
trates the data for all stages of endometriosis combined
and for minimal-mild and moderate-severe stages sepa-
rately (overall data for all cycle phases combined and
separate data according to phase of the menstrual
cycle). Figure 1A-D illustrates the data for moderate-
severe endometriosis (overall data for all cycle phases
combined and separate data according to phase of the
menstrual cycle). The area under the ROC curves
(AUC) were compared as described previously [23].
Superior diagnostic performance (higher AUC) was
demonstrated for the hsCRP assay when compared to
the classical CRP assay (Table 3; Figure 1A-D). Indeed,
the AUC was significantly higher for hsCRP analysis
than for classical CRP analysis for the diagnosis of mod-
erate-severe endometriosis in an overall analysis (all
cycle phases combined, p = 0.018) and for the diagnosis
of minimal-severe endometriosis during the luteal phase
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ability for the diagnosis of endometriosis was obtained
using the hsCRP assay during the luteal phase, especially
for moderate -severe endometriosis (AUC 0.76, Table 3;
Figure 1B). At a cut-off plasma level of hsCRP > 0.71
mg/L, moderate-severe stages of endometriosis were
diagnosed with sensitivity of 80.65% and specificity of
63.89% during the luteal phase of the menstrual cycle.
Using a similar cut-off value for CRP analyzed by the
classical method during the same luteal phase, moderate-
severe endometriosis was diagnosed (AUC 0.7, Table 3;
Figure 1B) with lower sensitivity (67.7%) and comparable
specificity (63.9%). However these differences in sensitiv-
ity were not statistically significant (p = 0.125 (two-tail)
or 0.0625 (one-tail)).
D u et oc o m p a r a b l ep l a s m aC R Pa n dh s C R Pl e v e l s
between women with stage I-II endometriosis and con-
trols (Table 2), the ROC curve analysis was not useful
and it was not possible to develop the optimal cut-off
point for the diagnosis of stage I-II endometriosis
(Table 3).
Determination of CRP in plasma: Comparison of classical
CRP and hsCRP assays
The number of plasma samples with detectable CRP was
significantly higher (295/295 or 100%) using the hsCRP
assay when compared to the classical CRP assay (126/295
or 42.7%) (p < 0.0001). Comparison of the CRP plasma
levels between the classical CRP assay and the hsCRP
assay showed a good Spearman correlation coefficient,
Table 2 Plasma hsCRP and CRP levels according to the cycle phase and disease stage
All
Phases
All
phases
Luteal
phase
Luteal
phase
Follicular
phase
Follicular
phase
Menstrual
phase
Menstrual
phase
CRP (mg/L) hsCRP(mg/L) CRP(mg/L) hsCRP(mg/L) CRP(mg/L) hsCRP(mg/L) CRP(mg/L) hsCRP(mg/L)
Controls 0.425 0.62 0.425 0.54 0.425 0.62 0.425 0.75
(0.425-14.6) (0.11-15.03) (0.425-6.3) (0.11-7.15) (0.425-10.3) (0.18-10.59) (0.425-14.6) (0.27-15.03)
Stage I-IV 0.425 0.88 0.425 0.89 0.425 0.64 0.425 0.95
(0.425-31.6) (0.06-37.22) (0.425-24.9) (0.12-27.23) (0.425-13.0) (0.06-14.22) (0.425-31.6) (0.6-37.22)
P values
(Mann-Whitney)
0.12 0.06 0.1 0.008 0.9 0.89 0.33 0.67
Stage I-II 0.425 0.64 0.425 0.66 0.425 0.49 0.425 0.87
(0.425-31.6) (0.06-37.22) (0.425-13.1) (0.12-14.14) (0.425-5.6) (0.06-6.6) (0.425-31.6) (0.15-37.22)
Stage III-IV 1.3 1.35 1.6 1.42 1 1.26 1.5 1.56
(0.425-30.5) (0.23-34.78) (0.425-24.9) (0.23-27.23) (0.425-13.0) (0.32-14.22) (0.425-30.5) (0.53-34.78)
P values
(Kruskal-Wallis)
< 0.0001 < 0.0001 0.0033 0.0005 0.038 0.0025 0.29 0.19
Table 3 ROC curve analysis for CRP and hsCRP
AUC Cut-off Sensitivity%/Specificity% AUC Cut-off Sensitivity %/Specificity%
CRP CRP CRP hsCRP hsCRP hsCRP
(mg/L) (mg/L)
All Phases
Controls vs Stage I-IV 0.55 > 0.71 45.6/63.7 0.57 > 0.62 61.8/50.6
Controls vs Stage I-II 0.50 N/A N/A 0.51 N/A N/A
Controls vs Stage III-IV 0.66 > 0.71 63.8/63.7 0.71 > 0.72 78.3/56.0
Luteal phase
Controls vs Stage I-IV 0.59 > 0.71 48.8/63.9 0.65 > 0.70 58.9/63.9
Controls vs Stage I-II 0.52 N/A N/A 0.59 > 0.54 57/50
Controls vs Stage III-IV 0.70 > 0.71 67.7/63.9 0.76 > 0.71 80.7/63.9
Follicular phase
Controls vs Stage I-IV 0.50 > 0.71 41.0/61.1 0.51 > 0.61 54.2/50
Controls vs Stage I-II 0,54 N/A N/A 0.57 N/A N/A
Controls vs Stage III-IV 0.62 > 0.71 60.9/61.1 0.70 > 0.66 78.3/52.8
Menstrual phase
Controls vs Stage I-IV 0.57 > 0.71 49.0/68.0 0.54 > 0.73 68.3/47.4
Controls vs Stage I-II 0.53 N/A N/A 0.53 N/A N/A
Controls vs Stage III-IV 0.63 > 0.71 60.0/68.4 0.65 > 0.78 80.0/52.6
N/A- not applicable.
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Page 4 of 9ranging between 0.74 and 0.997 (Table 4), which was sig-
nificantly higher (p < 0.001) in the endometriosis group
(0.996) than in the control group (0.74). The bias and
corresponding limits of agreement between two CRP
tests are listed in Table 4.
Discussion
To the best of our knowledge this is the first study which
evaluated and compared the diagnostic performance of
hsCRP and classical CRP assays in endometriosis based on
the comparison of ROC curves and diagnostic sensitivities
of these tests, as recommended by previous investigators
[19,24,25].
In this study we demonstrated that CRP plasma con-
centrations within the normal reference range (between
undetectable and 10 mg/L), as detected by the hsCRP
assay, confirm the presence of subclinical inflammation
in patients with endometriosis.
A
C
B
D
Figure 1 ROC of hsCRP and CRP for prediction of moderate-severe endometriosis. A: In an overall analysis (all cycle phases combined). The
AUC was significantly higher for hsCRP analysis than for classical CRP analysis for the diagnosis of moderate-severe endometriosis in an overall
analysis (all cycle phases combined, p = 0.018). B: In a luteal cycle phase. The AUC values of hsCRP and CRP were not significantly different (p =
0.065). C: In a follicular cycle phase. The AUC was higher for hsCRP analysis than for classical CRP analysis with borderline significance (p = 0.047).
D: In a menstrual cycle phase. The AUC values of hsCRP and CRP were not significantly different (p = 0.83).
Table 4 Comparison of two methods for the measurement of CRP in plasma
Total Controls Stage I-IV Stage I-II Stage III-IV
CRP mg/L 0.425 0.425 0.425 0.425 1.3
(0.425-31.6) (0.425-14.6) (0.425-31.6) (0.425-31.6) (0.425-30.5)
hsCRP mg/L 0.76
(0.06-37.22)
0.62
(0.11-15.03)
0.88
(0.06-37.22)
0.64
(0.06-37.22)
1.35
(0.23-34.78)
P values (Mann-Whitney) 0.92 0.77 0.759 0.68 0.46
Correlation coefficient (Spearman) 0.857 0.74 0.996 0.997 0.996
Bias -0.15 -0.06 -0.19 -0.096 -0.38
SD of Bias 0.87 1.18 0.69 0.54 0.88
95% Limits of agreement -1.85 and 1.55 -2.37 and 2.56 -0.56 and 1.15 -1.16 and 0.97 -2.10 and 1.35
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normally less than 10 mg/L and serum levels of CRP may
increase over 1000-fold following inflammation or infec-
tion [6,26,27]. In clinical practise only the levels of CRP
above the reference interval are considered as being of
clinical significant [6]. However, CRP concentrations
within the normal adult reference range provide valuable
information of chronic inflammatory processes like Heli-
cobacter pylori and Chlamydia pneumonia [6,28] and
also endometriosis, as demonstrated in our study. Rou-
tine CRP assays often do not quantify CRP concentra-
tions below the upper normal limit that may be relevant
to detect subclinical inflammation which may occur early
during disease development [29]. Such quantification is
possible using high sensitivity CRP assays, based on the
principle of particle-enhanced immunological agglutina-
tion or enzyme-linked immunosorbent assay [30].
In our study the hsCRP assay was superior to the classi-
cal CRP assay for the detection of subclinical inflammation
in plasma of endometriosis patients. Our results are in line
with the observations of other investigators [29,31], who
provided evidence for an additional value of hsCRP in the
clinical assessment of patients with Wegener’sG r a n u l o -
matosis, ankylosing spondylitis and non-radiographic axial
spondyloarthritis [29,31]. These authors reported that
hsCRP but not CRP levels, were higher in sera from
patients who subsequently relapsed versus those who did
not, indicating patients at risk [31]. In the mentioned stu-
dies, hsCRP levels were more closely associated with dis-
ease activity than CRP levels [29,31].
In our study, the hsCRP assay was superior to the classi-
cal CRP assay with respect to the proportion of plasma
samples with detectable levels of CRP (100% versus 43%)
and to its diagnostic performance (AUC, ROC curves, sen-
sitivity). The diagnostic performance of hsCRP was super-
ior to the diagnostic performance of classical CRP to
distinguish endometriosis from controls (especially stage
III-IV during the luteal cycle phase) (Table 3). Indeed the
AUC was significantly higher after hsCRP analysis than
after classical CRP analysis for the diagnosis of moderate-
severe endometriosis in combined analysis (all cycle
phases combined) and for minimal-severe endometriosis
(during the luteal phase of the cycle only). The optimum
cut-off value of plasma CRP > 0.71 mg/L obtained during
the luteal phase of the menstrual cycle could predict
nearly 13% more patients with moderate-severe endome-
triosis using the hsCRP assay when compared with the
classical CRP assay. This is an interesting observation
since our cut-off value (0.71 mg/L) was similar to the low-
est cut-off point used in the risk assessment algorithm in
the primary prevention of Cardiovascular disease [6,32]. In
that survey, a mild relative risk of future cardiovascular
disease was determined using low plasma levels of hsCRP
between 0.7 -1.1 mg/L [32]. Although both endometriosis
and atherosclerosis are associated with oxidative stress
[33], at present there is no evidence that women with
endometriosis have an increased risk for cardiovascular
disease and atherosclerosis.
Comparable plasma CRP levels between women with
endometriosis and controls (Table 2) resulted in a low
AUC (0.55, Table 3) demonstrating limited clinical
value.
Plasma CRP and hsCRP levels were comparable in
women with stage I-II of endometriosis and controls
(Table 2), resulting in low AUCs (0.50-0.57, Table 3),
that did not allow determination of any cut-off points,
demonstrating no clinical value.
The strength of this study lies in the fact that compar-
ison of the diagnostic performance of hsCRP and CRP
assays was evaluated on a large number of patients with
laparoscopically confirmedo re x c l u d e de n d o m e t r i o s i s
during all phases of the menstrual cycle.
The rationale for separating the different phases of the
menstrual cycle is justified by the following observations.
Firstly, according to QUADAS (Quality Assessment of
Diagnostic Accuracy Studies) guidelines [15,16], samples
should be collected at a consistent phase of the cycle and
results should be corrected for the cycle phases. Sec-
ondly, according to a recently published systematic
review, lack of correction for the phase of the menstrual
cycle can explain the considerable variability between
studies with respect to blood levels of biomarkers in
women with endometriosis and controls [15]. For
instance, such correction was absent in three of the nine
reviewed papers investigating IL-6 as a biomarker for
endometriosis, despite evidence that levels are known to
change throughout the cycle [15,34].
Thirdly, CRP levels in peripheral blood have been
reported to be significantly higher during the midcycle and
luteal phase when compared to the follicular phase [35].
Comparison of our results with those from other studies
reporting CRP levels in women with endometriosis is diffi-
cult (Table 5) due to differences in patient phenotype,
patient number, type of peripheral blood (serum or plasma)
and CRP methodology (variety of assays manufactured by a
variety of companies) [11-14,36]. The sensitivity of the CRP
assay is crucial for measurements of analytes with low con-
centrations. However, using a hsCRP assay, no differences
were found in serum CRP levels between women with and
without endometriosis in 2 studies [12,13], including a
much smaller number of patients (n = 38 and n = 82,
respectively) than in our study. The high correlation
between hsCRP and classical CRP assays observed in our
study (Table 4) confirms data reported before [13].
In conclusion, the hsCRP assay was superior to the
classical CRP assay for the detection of low CRP levels
indicating subclinical inflammation in plasma of endo-
metriosis patients. Diagnostic performance of hsCRP
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severe endometriosis. However, CRP is not useful for
diagnosis of early stages of endometriosis.
List of abbreviations
CRP: C-reactive protein; hs: high sensitivity; ROC: receiver operating
characteristic; LUFC: Leuven University Fertility Centre; LLD: lower limit of
detection; AUC: areas under the ROC curves.
Table 5 Performance of CRP as a biomarker for endometriosis
Authors Type of study Controls Endometriosis Methodology Results
Abrao
et al.,
1997
Case-control study N = 15
Time 1
Menstrual
phase μg/
ml:
1.58 ± 0.31
Time 2:
Proliferative
phase μg/
ml:
1.53 ± 0.33
N=3 5
Stage I-II = 20
Stage III-IV =
15
Menstrual
phase μg/ml:
Stage I-II: 5.06
± 1.32
Stage III-IV:
13.15 ± 2.55
Proliferative
phase μg/ml:
Stage I-II: 2.89
± 0.59
Stage III-IV:
3.52 ± 0.41
Serum
Laparoscopically confirmed or
excluded endometriosis
Menstrual and Proliferative
phases of cycle
Home-made ELISA
Difference: Time1-Time 2
Controls: 0.05 ± 0.38
Stage I-II: 2.17 ± 1.16
Stage III-IV: 9.63 ± 2.34
Increased levels of CRP in endometriosis (especially
for stages III-IV)
Lermann
et al.,
2010
Prospective
nonrandomized
controlled trial
N=3 4
CRP: 2.88 ±
2.79 ng/ml
hsCRP: 2.48
± 3.77 ng/
ml
N=4 8
Stage I: 7
Stage II: 5
Stage III: 18
Stage IV: 18
CRP: 3.54 ±
3.24
hsCRP: 3.61 ±
4.82
Serum
Laparoscopically confirmed or
excluded endometriosis
Early Proliferative cycle phase
CRP and hsCRP methods (details
Not Available)
NS differences
Matarese
et al.,
2000
Case-control study N = 15 N = 13
Stage I-II: 7
Stage III-IV: 6
Serum
Laparoscopically confirmed or
excluded endometriosis
Proliferative and secretive cycle
phase
N Latex CRP monokit (Bering
Nephelometer Systems)
CRP serum concentrations were less than 3.5 mg/L
in all subjects
Mihalyi
et al.,
2010
Case-control study N = 93
All phases:
0.64 (0.11-
15.03) mg/L
Secretory
phase
0.56 (0.11-
14.14) mg/L
N = 201
All phases
Stage III-IV:
1.35 (0.23-
34.78) mg/L
Secretory
phase
Stage I-IV:
0.88 (0.12-
27.23) mg/L
EDTA Plasma
Laparoscopically confirmed or
excluded endometriosis
Menstrual, Proliferative and
Secretory phases
hsCRP method: HS Tina-quant
CRP (latex) hs assay (Roche,
Vilvoorde, Belgium)
Significant increase in Stage III-IV (independent of
cycle phase and in the luteal phase (p < 0.0001; p
= 0.001respectively)
Significant increase in Stage I-IV of endometriosis
in the luteal phase (p = 0.03)
Xavier
et al.,
2005
Case-control study N = 13
Early
proliferative:
0.68 (0.19-
2.22) mg/L
Late
proliferative:
0.59 (0.21-
1.28) mg/L
Early
secretory:
0.90 (0.42-
2.31) mg/L
Late
secretory:
0.87 (0.22-
1.52) mg/L
N=2 5
Stage III-IV
Early
proliferative:
2.29 (0.70-3.54)
mg/L
Late
proliferative:
1.10 (0.30-2.06)
mg/L
Early secretory:
1.09 (0.39-2.62)
mg/L
Late secretory:
0.60 (0.28-3.19)
mg/L
Serum
Early and late Proliferative phase
Early and late Secretory phase
hsCRP two-site homemade ELISA
NS differences
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